DrugPatentWatch Database Preview
Clovis Oncology Inc Company Profile
What is the competitive landscape for CLOVIS ONCOLOGY INC, and what generic alternatives to CLOVIS ONCOLOGY INC drugs are available?
CLOVIS ONCOLOGY INC has one approved drug.
There are twelve US patents protecting CLOVIS ONCOLOGY INC drugs.
There are two hundred and twenty-seven patent family members on CLOVIS ONCOLOGY INC drugs in fifty-three countries and twenty-five supplementary protection certificates in seventeen countries.
Summary for Clovis Oncology Inc
| International Patents: | 227 |
| US Patents: | 12 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Clovis Oncology Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 9,045,487 | Start Trial | Y | Y | Start Trial | ||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 8,754,072 | Start Trial | Y | Y | Start Trial | ||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | 8,143,241 | Start Trial | Start Trial | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | Start Trial | Start Trial | |||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | 6,495,541 | Start Trial | Y | Y | Start Trial | ||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | 7,531,530 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Clovis Oncology Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2533332 | Start Trial |
| Lithuania | C1633724 | Start Trial |
| Austria | 508118 | Start Trial |
| Austria | 454893 | Start Trial |
| Eurasian Patent Organization | 200501434 | Start Trial |
| Australia | 2010202197 | Start Trial |
| Eurasian Patent Organization | 004989 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Clovis Oncology Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1633724 | C20150012 00136 | Estonia | Start Trial | PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014 |
| 1633724 | CR 2015 00012 | Denmark | Start Trial | PRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216 |
| 2534153 | C20180033 00273 | Estonia | Start Trial | PRODUCT NAME: RUKAPARIIB;REG NO/DATE: EU/1/17/1250 29.05.2018 |
| 2534153 | 122018000131 | Germany | Start Trial | PRODUCT NAME: RUCAPARIB CAMSYLAT; REGISTRATION NO/DATE: EU/1/17/1250 20180524 |
| 1633724 | 15C0022 | France | Start Trial | PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218 |
| 2534153 | LUC00093 | Luxembourg | Start Trial | PRODUCT NAME: RUCAPARIB CAMSYLATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1250 20180529 |
| 2534153 | 2018039 | Norway | Start Trial | PRODUCT NAME: RUKAPARIBKAMSYLAT; REG. NO/DATE: EU/1/17/1250 20180531 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
